Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.73 |
| ▸ | CA1 | P00915 | 4/20 | 0.73 |
| ▸ | CA12 | O43570 | 3/20 | 0.73 |
| ▸ | CA9 | Q16790 | 3/20 | 0.73 |
| ▸ | CA3 | P07451 | 1/20 | 0.73 |
| ▸ | CA6 | P23280 | 1/20 | 0.73 |
| ▸ | CA5A | P35218 | 1/20 | 0.73 |
| ▸ | CA7 | P43166 | 1/20 | 0.73 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.73 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.73 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indisulam SCHEMBL91389 | 0.85 | CA1 (1.00) | CA2CA1CA12CA9CA3 | |
| Indisulam SCHEMBL29799438 | 0.85 | CA1 (1.00) | CA2CA1CA12CA9CA3 | |
| SCHEMBL14536224 | 0.84 | CA1 (0.80) | CA2CA1CA12CA9CA3 | |
| SCHEMBL3062409 | 0.84 | CA1 (0.83) | CA2CA1CA12CA9CA3 | |
| SCHEMBL3073932 | 0.84 | CA1 (0.79) | CA2CA1CA12CA9CA3 | |
| SCHEMBL7006391 | 0.84 | CA1 (0.79) | CA2CA1CA12CA9CA3 | |
| SCHEMBL27634530 | 0.84 | CA1 (0.79) | CA2CA1CA12CA9CA3 | |
| SCHEMBL3068188 | 0.84 | CA1 (0.79) | CA2CA1CA12CA9CA3 | |
| SCHEMBL30241727 | 0.81 | CA1 (0.75) | CA2CA1CA12CA9CA3 | |
| SCHEMBL12190471 | 0.81 | CA1 (0.79) | CA2CA1CA12CA9CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| CN-100356979-C | Integrin expression inhibitors | EISAI CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1433479-B1 | APPETITE-STIMULATING AGENTS AND REMEDIES FOR ANOREXIA | EISAI R&D MAN CO LTD (JP) | 2007-12-05 | — | — | EP | disclosed |
| US-7015241-B2 | Appetite-stimulating agents and remedies for anorexia | EISAI CO., LTD. (JP) | 2006-03-21 | — | — | US | disclosed |
| CN-1221533-C | Heterobicyclic sulfonamide derivative and sulfonic ester derivative | EISAI CO LTD (JP) | 2005-10-05 | — | — | CN | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-20040242628-A1 | Appetite-stimulating agents and remedies for anorexia | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| CN-1551766-A | Lymphocytic activation inhibitor and remedial agent for autoimmune disease | ������������ʽ���� | 2004-12-01 | — | — | CN | disclosed |
| US-20040235866-A1 | Lymphocytic activation inhibitor and remedial agent for autoimmune disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1433479-A1 | APPETITE-STIMULATING AGENTS AND REMEDIES FOR ANOREXIA | Eisai Co., Ltd (JP) | 2004-06-30 | — | — | EP | disclosed |
| EP-1430894-A1 | LYMPHOCYTIC ACTIVATION INHIBITOR AND REMEDIAL AGENT FOR AUTOIMMUNE DISEASE | Eisai Co. Ltd (JP) | 2004-06-23 | — | — | EP | disclosed |
| CN-1491941-A | Heterobicyclic sulfonamide derivative and sulfonic ester derivative | ������������ʽ���� | 2004-04-28 | — | — | CN | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-0673937-B1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | EISAI CO LTD (JP) | 2003-11-26 | — | — | EP | disclosed |
| CN-1396833-A | Integrin expression inhibitors | EISAI CO LTD (JP) | 2003-02-12 | — | — | CN | disclosed |
| CN-1079097-C | Heterobicyclic sulfonamide derivatives and sulfonate derivatives | EISAI CO LTD (JP) | 2002-02-13 | — | — | CN | disclosed |
| CN-1114506-A | Heterobicyclic sulfonamide derivatives and sulfonate derivatives | EISAI CO LTD (JP) | 1996-01-03 | — | — | CN | disclosed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | CA2 821/4885CA1 867/4885CA12 513/4885 |
| US-20040235866-A1 | Lymphocytic activation inhibitor and remedial agent for autoimmune disease | NFATC1, CHUK, CD4 | CA2 49/4885CA1 44/4885CA12 607/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | CA2 821/4885CA1 867/4885CA12 513/4885 |
| US-20040242628-A1 | Appetite-stimulating agents and remedies for anorexia | GHSR, CCKAR, SUCNR1 | CA2 208/4885CA1 219/4885CA12 452/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | CA2 631/4885CA1 827/4885CA12 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.